1st Advances in Rare Bone Diseases Conference

描述(由申请人提供)：申请R13的支持将在一定程度上提供举办一次关于罕见骨病的科学和患者互动会议的手段。它将被命名为“罕见骨病的第一进展，(ARBD-1)”，并将于2008年10月23-24日在国立卫生研究院校园的贝塞斯达举行。会议的目标是(1)考察与一系列遗传性骨骼疾病有关的基础、翻译和临床研究的最新进展；(2)了解科学的最新进展如何应用于骨生物学和临床骨学领域；(3)允许选定的受训者和初级教员向该领域的专家观众展示他们的相关工作；(4)让感兴趣的非专业观众与这些骨骼疾病的科学和医学专家以及涉及骨骼和孤儿疾病的制药业进行互动；以及(5)建立对研究和治疗的新的理解和需求。受邀专家和与会者将代表不同的学科，包括遗传学、分子生物学、纳米生物学、内分泌学、风湿学、肾脏病、胃肠病学、营养学、运动生理学、骨科、放射学、人类学、免疫学、细胞生物学和生物机械工程等。会议联席主任和作为项目委员会的16名知名国际骨骼研究人员制定了一个为期2天的科学计划，其中包括总体全体演讲、指导最先进的演示、食品和药物管理局、涉及以罕见骨骼疾病为代表的孤儿疾病的制药业的邀请讲座，以及针对7个特定疾病实体的热点话题讨论。国家关节炎、肌肉骨骼和皮肤病研究所以及罕见疾病办公室已经批准了这一申请，并批准了其提交。对R13的支持请求将在一定程度上提供举办一次关于罕见骨病的科学和患者互动会议的手段。它将被命名为“罕见骨病的第一进展，(ARBD-1)”，并将于2008年10月23-24日在国立卫生研究院校园的贝塞斯达举行。会议的主要目标是提供影响骨骼的罕见疾病的最新研究和临床信息，并扩大和进一步发展研究界和致力于为患有这些疾病的患者提供服务的非专业组织之间的伙伴关系。FDA和企业科学家都将参加这次交流。此外，这次会议还将促进将生物医学研究领域的最新技术转让给在罕见骨病领域工作的研究人员。

DESCRIPTION (provided by applicant): This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The objectives of the conference are (1) to examine the latest advances in basic, translational, and clinical research relating to a series of genetic bone diseases (2) to understand how recent advances in science may be applied to the areas of bone biology and clinical osteology (3) to allow selected trainees and junior faculty to present their relevant work to an audience of experts in the field, (4) to have an interested lay audience interact with scientific and medical experts in these bone diseases, and the pharmaceutical industry involved in bone and orphan diseases and (5) to forge new areas of understanding and need for research and therapeutics. Invited experts and attendees will represent diverse disciplines that include genetics, molecular biology, nanobiology, endocrinology, rheumatology, nephrology, gastroenterology, nutrition, exercise physiology, orthopedics, radiology, anthropology, immunology, cell biology, and biomechanical engineering, among others. The conference co-directors, and sixteen established, international bone investigators serving as the Program Committee have developed a 2-day scientific program that includes overarching plenary lectures, directed state of the art presentations, invited lectures from the Food and Drug Administration, the pharmaceutical industry involved in orphan diseases represented by rare bone diseases, and Hot Topic discussions for seven specific disease entities. The National Institute for Arthritis, Musculoskeletal and Skin Diseases, along with the Office of Rare Diseases, has endorsed this application and granted permission for its submission. This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The key objectives of the conference are to provide the latest research and clinical information on rare diseases affecting the skeleton and to extend and further develop partnerships between the research community and lay organizations dedicated to serving patients with these diseases. Both the FDA and corporate scientists will participate in this exchange. Additionally, this conference will facilitate transfer of the latest technology from the biomedical research community to investigators working in the rare bone disease field.